Survey data from 104 US rheumatologists point to guarded enthusiasm for cell therapy in autoimmune disease: most hold favorable impressions of emerging chimeric antigen receptor T-cell data, and nearly half anticipate a first-line role in systemic sclerosis. Enthusiasm is tempered by concerns about infection risk, cytokine release syndrome, and neurotoxicity, along with affordability, access, and durability of remission. Few believe the risks outweigh the benefits, but clinicians broadly want longer follow-up and practical delivery frameworks before envisioning widespread use.

The immediate news is a new Spherix Global Insights report capturing how rheumatologists expect cell therapy to slot into care. Systemic sclerosis stands out as the condition where physicians could move CAR T earlier in the algorithm, reflecting limited effective options and high morbidity. For lupus nephritis, idiopathic inflammatory myopathies, and other indications, clinicians expect cell therapy to remain a later-line choice after multiple biologics and immunosuppressants. Most foresee implementation at academic medical centers and prefer co-management with hematology, signaling a near-term concentration of trials and treatment in specialized hubs rather than community settings.

Strategically, the findings validate a wave of investment by sponsors developing autoimmune CAR T as an “immune reset” approach, but they also sharpen the bar for clinical and operational proof. The oncology playbook will not be sufficient. Autoimmune indications will require evidence of durable, steroid-sparing benefit with manageable toxicity in populations that are often younger and chronically treated. That implies trial designs emphasizing sustained remission and organ function over longer horizons, alongside robust safety monitoring beyond the initial 90 days. It also raises commercial and regulatory tensions: the promise of potentially transformative outcomes versus the realities of inpatient resources, chain-of-identity logistics, and payer scrutiny for six-figure, single-administration therapies in nonmalignant disease.

The ripple effects are immediate for clinical execution. Sites without hematology/oncology cell therapy infrastructure are unlikely to participate early, pushing sponsors and CROs to cluster studies at accredited centers with apheresis, ICU backup, and experience managing CRS/ICANS. That concentration may speed start-up but complicate enrollment diversity in diseases like systemic sclerosis, where disparities are well documented. CROs will need to blend autoimmune expertise with cell therapy operational know-how, including vein-to-vein tracking, complex SAE adjudication, and long-term follow-up infrastructure. Vendors supporting apheresis networks, cold chain, cell processing, and centralized safety monitoring stand to play outsized roles. Regulators will expect multi-year follow-up, clear definitions of remission and retreatment, and mitigation plans that keep risk profiles acceptable outside oncology settings.

The next milestones to watch are pivotal trial designs in systemic sclerosis and refractory lupus cohorts, including the choice of primary endpoints, duration of follow-up, and comparator strategies. Early-line positioning in systemic sclerosis will likely require rigorous head-to-head or add-on designs against current standards, not single-arm signals. Manufacturing scalability and release timelines will be under scrutiny as enrollment expands beyond a handful of centers. Sponsors exploring allogeneic or low-toxicity constructs may gain operational advantages if they can show comparable durability. Finally, hub-and-spoke care models that extend expertise from academic centers to regional sites could become a differentiator for both trials and eventual access. The signal from clinicians is clear: cell therapy has momentum in rheumatology, but its path to routine use runs through durability, safety, and delivery models that the current system can realistically support.

Source link: https://www.globenewswire.com/news-release/2025/10/06/3161902/0/en/US-Rheumatologists-View-Cell-Therapy-as-a-Potential-Game-Changer-with-Systemic-Sclerosis-Emerging-as-the-Most-Compelling-Indication-According-to-Spherix-Global-Insights.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.